Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
Inc. (Nasdaq: SGMO) announced today that
and CEO, will provide an update on the progress of Sangamo’s ZFP Therapeutic
development programs and an overview of the company’s business strategy at
The presentation will be webcast live and may be accessed via a link on
the Sangamo BioSciences website in the Investor Relations section
http://investor.sangamo.com/index.cfm under Events and Presentations. The
presentation will be archived on the Sangamo website for two weeks after the
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification.
The most advanced ZFP Therapeutic(TM) development program is currently in
Phase 2 clinical trials for evaluation of safety and clinical effect in
patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS).
Other therapeutic development programs are focused on HIV/AIDS, cancer,
neuropathic pain, nerve regeneration, Parkinson’s disease and monogenic
diseases. Sangamo’s core competencies enable the engineering of a class of
DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By
engineering ZFPs that recognize a specific DNA sequence Sangamo has created
ZFP transcription factors (ZFP TF(TM)) that can control gene expression and,
consequently, cell function. Sangamo is also developing sequence-specific ZFP
Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic
partnerships with companies in non-therapeutic areas including Dow
AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology
to enhance the production of protein pharmaceuticals. For more information
about Sangamo, visit the company’s web site at http://www.sangamo.com.
This press release may contain forward-looking statements based on
Sangamo’s current expectations. These forward-looking statements include,
without limitation, references to the research and development of novel ZFP
TFs and ZFNs as ZFP Therapeutics, applications of Sangamo’s ZFP TF technology
platform, strategic partnerships with collaborators and clinical trials of ZFP
Therapeutics. Actual results may differ materially from these forward-looking
statements due to a number of factors, including technological challenges,
uncertainties relating to the initiation and completion of stages of ZFP
Therapeutic clinical trials, Sangamo’s ability to develop commercially viable
products and technological developments by our competitors. See the company’s
SEC filings, and in particular, the risk factors described in the company’s
Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo
BioSciences, Inc. assumes no obligation to update the forward-looking
information contained in this press release.
SOURCE Sangamo BioSciences, Inc.